D. E. Shaw & Co. Inc. raised its holdings in shares of Cardlytics, Inc. (NASDAQ:CDLX – Free Report) by 97.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,131,505 shares of the company’s stock after purchasing an additional 558,235 shares during the period. D. E. Shaw & Co. Inc. owned 2.23% of Cardlytics worth $4,198,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in CDLX. Mirabella Financial Services LLP bought a new position in shares of Cardlytics during the fourth quarter valued at approximately $4,285,000. Rangeley Capital LLC bought a new position in shares of Cardlytics during the fourth quarter valued at approximately $1,187,000. RBF Capital LLC increased its stake in shares of Cardlytics by 64.7% during the fourth quarter. RBF Capital LLC now owns 803,763 shares of the company’s stock valued at $2,982,000 after purchasing an additional 315,635 shares in the last quarter. Natixis bought a new position in shares of Cardlytics during the fourth quarter valued at approximately $462,000. Finally, Bridgeway Capital Management LLC bought a new stake in shares of Cardlytics during the fourth quarter valued at approximately $416,000. Institutional investors own 68.10% of the company’s stock.
Cardlytics Trading Up 3.5%
NASDAQ:CDLX opened at $2.06 on Friday. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. Cardlytics, Inc. has a 12 month low of $1.22 and a 12 month high of $9.85. The company has a market cap of $108.15 million, a PE ratio of -0.34 and a beta of 1.30. The company has a 50 day simple moving average of $1.81 and a two-hundred day simple moving average of $2.90.
Insiders Place Their Bets
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on CDLX. Lake Street Capital reduced their price target on shares of Cardlytics from $3.00 to $2.50 and set a “hold” rating for the company in a research report on Thursday, May 8th. Needham & Company LLC reissued a “hold” rating on shares of Cardlytics in a research report on Thursday, March 13th. Finally, Evercore ISI reduced their price target on shares of Cardlytics from $4.00 to $3.00 and set an “in-line” rating for the company in a research report on Thursday, March 13th. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $5.20.
View Our Latest Analysis on Cardlytics
Cardlytics Profile
Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.
Featured Articles
- Five stocks we like better than Cardlytics
- Consumer Staples Stocks, Explained
- Top 4 ETFs for China Exposure After Tariff Relief
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Build a Complete Bond Portfolio With These 4 ETFs
- Large Cap Stock Definition and How to Invest
- MarketBeat Week in Review – 05/12 – 05/16
Want to see what other hedge funds are holding CDLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardlytics, Inc. (NASDAQ:CDLX – Free Report).
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.